What it's for (Indications)
- Filgrastim (Filatil) is a recombinant human granulocyte colony-stimulating factor (G-CSF) indicated for several critical conditions involving neutropenia, a deficiency of neutrophils (a type of white blood cell essential for fighting infections).
- Its primary use is to decrease the incidence of infection, manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia.
- Additionally, filgrastim is indicated for the reduction in the duration of neutropenia and neutropenia-related clinical sequelae in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.
- It is also used for the mobilization of autologous peripheral blood progenitor cells (PBPCs) for collection by leukapheresis, severe chronic neutropenia (SCN) in adults and pediatric patients, and in patients with acute myeloid leukemia (AML) receiving induction or consolidation chemotherapy.
- The strategic application of filgrastim aims to bolster the body's immune defense during periods of vulnerability, thereby minimizing infectious complications and allowing for more effective and timely delivery of cancer treatments.
- This multifaceted utility underscores its importance in oncology and hematology.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of filgrastim (Filatil) is highly individualized and contingent upon the specific indication, patient's body weight, and response to therapy, as monitored by neutrophil counts. For patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, the recommended starting dose is typically 5 mcg/kg/day, administered as a single daily subcutaneous injection or short intravenous infusion. This dosage is continued until the absolute neutrophil count (ANC) has reached or surpassed 10,000 cells/mm³ after the expected nadir. In the context of myeloablative chemotherapy followed by bone marrow transplantation, the recommended dose is 10 mcg/kg/day, given as a subcutaneous injection or intravenous infusion. For peripheral blood progenitor cell mobilization, the recommended dose is 10 mcg/kg/day subcutaneously. For severe chronic neutropenia, the initial dose is generally 5 mcg/kg/day subcutaneously, with adjustments made based on the patient’s ANC to maintain counts above 1,500 cells/mm³. In all instances, treatment duration and dose adjustments should be guided by clinical response, hematologic parameters, and the prescribing physician's assessment, ensuring optimal therapeutic outcomes while minimizing potential adverse effects. |
Safety & Warnings
Common Side Effects
- Filgrastim (Filatil) is generally well-tolerated, but like all medications, it can cause a range of side effects, some of which can be serious.
- Common adverse reactions include musculoskeletal pain, predominantly bone pain (especially in the lower back, arms, and legs), which can often be managed with non-opioid analgesics.
- Other frequently reported side effects encompass fatigue, headache, nausea, vomiting, diarrhea, alopecia, and fever.
- More serious, albeit less common, adverse events include splenic rupture, which may present as left upper abdominal pain, left shoulder pain, or generalized abdominal pain; acute respiratory distress syndrome (ARDS) characterized by sudden onset of respiratory distress; and serious allergic reactions, including anaphylaxis, which manifest with symptoms such as rash, urticaria, facial swelling, dyspnea, or hypotension.
- Additionally, patients may experience glomerulonephritis, manifesting as hematuria or proteinuria, and capillary leak syndrome, which can cause hypotension, edema, and hypoalbuminemia.
- Myeloid malignancies and myelodysplastic syndrome have been observed in some populations, particularly in severe chronic neutropenia.
- Regular monitoring for these and other potential adverse effects is crucial during filgrastim therapy.
Serious Warnings
- Black Box Warning: **There is no formal FDA Black Box Warning associated with filgrastim (Filatil).** However, several serious and potentially life-threatening adverse events warrant significant attention and are routinely emphasized in product labeling and clinical guidelines as critical safety considerations. These serious warnings include, but are not limited to: 1. **Splenic Rupture:** Cases of splenic rupture, some fatal, have been reported following filgrastim administration. Patients presenting with left upper abdominal pain, left shoulder pain, or generalized abdominal pain should be evaluated immediately for an enlarged or ruptured spleen. This risk is particularly noted in healthy donors undergoing peripheral blood progenitor cell mobilization. 2. **Acute Respiratory Distress Syndrome (ARDS):** ARDS has been reported in patients receiving G-CSF products. Patients who develop fever, lung infiltrates, or respiratory distress should be evaluated for ARDS and, if diagnosed, receive appropriate supportive care. 3. **Serious Allergic Reactions:** Severe allergic reactions, including anaphylaxis, have occurred. Symptoms can include rash, urticaria, facial swelling, dyspnea, and hypotension. Discontinue filgrastim permanently in patients who experience a serious allergic reaction. 4. **Sickle Cell Crisis:** Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell trait or sickle cell disease receiving filgrastim. Use filgrastim with caution in patients with sickle cell trait or sickle cell disease and only after careful consideration of the potential risks and benefits. 5. **Glomerulonephritis:** Glomerulonephritis has been reported in patients receiving filgrastim. Diagnosis is usually made by kidney biopsy and resolves with dose reduction or discontinuation of filgrastim. 6. **Capillary Leak Syndrome:** Capillary Leak Syndrome (CLS), a rare but potentially life-threatening condition characterized by hypotension, hypoalbuminemia, and edema, has been reported following G-CSF administration. If symptoms develop, patients should be closely monitored and receive appropriate supportive care. These serious safety concerns necessitate vigilant monitoring and prompt intervention by healthcare providers to mitigate risks.
- Filgrastim (Filatil) carries several important warnings that healthcare professionals and patients must be aware of to ensure safe and effective use.
- A critical warning pertains to splenic rupture, which has been reported following administration of G-CSF, particularly during peripheral blood progenitor cell mobilization in healthy donors.
- Patients should be informed about the symptoms of splenic rupture, including left upper abdominal or shoulder pain, and advised to seek immediate medical attention if these occur.
- Acute respiratory distress syndrome (ARDS) has also been reported in patients receiving filgrastim; patients developing fever, lung infiltrates, or respiratory distress should be evaluated for ARDS and receive appropriate supportive care.
- Serious allergic reactions, including anaphylaxis, can occur, and treatment should be discontinued if these develop.
- Sickle cell crises have been reported in patients with sickle cell trait or sickle cell disease, thus filgrastim should be used with caution in these individuals.
- Glomerulonephritis has been observed, and patients should be monitored for signs such as hematuria and proteinuria.
- Capillary Leak Syndrome is another serious, potentially life-threatening condition associated with G-CSF administration.
- The potential for filgrastim to act as a growth factor for certain tumor types, particularly myeloid malignancies, should be considered, and it should not be used in patients with congenital neutropenia and cytogenetic abnormalities.
- Careful monitoring and patient education are paramount.
How it Works (Mechanism of Action)
Filgrastim (Filatil) is a pharmaceutical analogue of granulocyte colony-stimulating factor (G-CSF), a naturally occurring cytokine. Its primary mechanism of action involves binding to specific G-CSF receptors expressed on hematopoietic progenitor cells and mature neutrophils. This binding initiates a cascade of intracellular signaling pathways, including the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, the mitogen-activated protein kinase (MAPK) pathway, and the phosphatidylinositol 3-kinase (PI3K) pathway. These signaling events lead to the proliferation, differentiation, and commitment of myeloid progenitor cells in the bone marrow, specifically stimulating the production of neutrophils. Furthermore, filgrastim enhances the functional activity of mature neutrophils, improving their phagocytic capacity, priming them for oxidative burst, and increasing their chemotaxis. It also plays a crucial role in mobilizing hematopoietic stem cells from the bone marrow into the peripheral blood, making them accessible for collection, which is vital for peripheral blood progenitor cell transplantation. By accelerating neutrophil recovery and enhancing neutrophil function, filgrastim effectively mitigates the risk and severity of infection in neutropenic patients.